drugset / Trial / NCT00434031
CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the rate of pathologic complete response when giving docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and trastuzumab before surgery in treating women with operable or locally advanced HER-2 positive breast cancer.
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |